SLP
Simulations Plus, Inc.
SLP
18.46USD
+0.22%
Sep 25, 2026
Price
Loading price history…
Price Action
No clear price read
Longer-term context reads early recovery, with a near-term setup of daily advance.
EntryEarly recovery
The structure is repairing early: weekly fast averages are being reclaimed and the daily chart is recovering constructively — an early-recovery entry profile.
Key Financials
- Market Cap
- $373.4M
- Avg Volume (60D)
- 194.4K
- Revenue Growth YoY
- +13.1%
- Gross Margin
- +63.4%
- Operating Margin
- +14.0%
- Free Cash Flow Yield
- +6.6%
- Distance from 200DMA
- +12.6%
- Next Earnings
- 2026-10-29
- P/E
- 46.1x
- EV / EBITDA
- 18.9x
- EV / Sales
- 3.9x
60 sessions
FY2025 vs FY2024
Trailing twelve months
Trailing twelve months
Market metrics as of Sep 24, 2026
Financial results for the period ended May 31, 2026
Filed balance-sheet data as of Aug 31, 2022
Fundamentals & Valuation
Both valuation perspectives agree this company is fair.
Simulations Plus, Inc. has a Fair valuation stance because the price broadly reflects how much growth and cash flow it delivers per turn of revenue multiple, with upside and risk reasonably balanced.
Company Research
Thesis
Simulations Plus is a specialized software-and-services enabler for biopharma R&D, supplying modeling platforms and scientific consulting used to predict drug behavior, assess safety and efficacy, and support development and regulatory decisions.
Opportunity
Moderate opportunity
Biopharma adoption of mechanistic modeling, pharmacometrics, PBPK/QSP simulation, and AI-assisted evidence generation to improve drug discovery, trial design, dose selection, and regulatory submissions.
Key risk
Dependence on pharmaceutical R&D budgets.
Narrative & Theme
AI-Enabled Drug Development Modernization
Part of Model-Informed Drug Development and Biosimulation, with strong fit.
SLP has a direct and credible revenue connection to model-informed, increasingly AI-assisted drug development rather than a generic healthcare-AI association.
Narrative HeatNeutral5.8 / 10
This reading is no longer current (last measured 2026-08-27). It is kept until the next scheduled measurement replaces it.
Theme HeatNeutral6.6 / 10
This is the company’s own research reading. The canonical heat measurement for this story has not run.
Business & Markets
Healthcare · Health Information Services
What they do
Simulations Plus, Inc. develops software for drug discovery and development, using modeling, simulation, and AI/ML technologies to predict molecular properties and pharmacokinetics. It operates through Software and Services segments worldwide.
How it earns
The company generates revenue primarily through software licensing and service contracts.
Products & services
GastroPlus
DDDPlus
MembranePlus
DILIsym
NAFLDsym
ILDsym
IPFsym
RENAsym
MITOsym
OBES
Customers & end markets
Pharmaceutical and biotechnology companies
Academic and research institutions
Market position
Niche player specializing in AI-driven drug development simulation software.
Demand drivers
Medium cyclicality
Demand is linked to pharmaceutical R&D spending, which can fluctuate with industry cycles and regulatory environments.